Page 372 - SAHCS HIVMed Journal Vol 20 No 1 2019

Page 11 of 12 Original Research

project funding, as well as oversight of surveillance, data 8. Bengtson AM, Chibwesha CJ, Westreich D, et al. Duration of cART before delivery
and low infant birthweight among HIV-infected women in Lusaka, Zambia. J
capture and quality improvement activities at the sites and Acquir Immune Defic Syndr. 2016;71(5):563–569. https://doi.org/10.1097/
served as members of the project steering committee. A.N. QAI.0000000000000909
and F.R. provided technical and administrative support to 9. Li N, Sando MM, Spiegelman D, et al. Antiretroviral therapy in relation to
birth outcomes among HIV-infected women: A cohort study. J of Infect Dis.
the National Department of Health for surveillance 2016;213(7):1057–1064. https://doi.org/10.1093/infdis/jiv389
activities. N.F.M. served as a member of the steering 10. Chen JY, Ribaudo HJ, Souda S, et al. Highly active antiretroviral therapy and
adverse birth outcomes among HIV-infected women in Botswana. J Infect Dis.
committee, providing technical support throughout the 2012;206(11):1695–1705. https://doi.org/10.1093/infdis/jis553
project. K.F. and M.F.U. served as members of the U.C.M. 11. Siemieniuk RA, Foroutan F, Mizra R, et al. Antiretroviral therapy for pregnant
women living with HIV or Hepatitis B: A systematic review and meta-analysis. BMJ
review panel. M.F.U. assisted with the development of the Open. 2017;7(9):e019022. https://doi.org/10.1136/bmjopen-2017-019022
data collection tools, and K.F. provided further technical 12. Zash R, Makhema J, Shapiro RL. Neural-tube defects with dolutegravir treatment
from the time of conception. N. Engl J Med. 2018;379(10):979–981. https://doi.
support during data analysis. S.K. served as the data org/10.1056/NEJMc1807653
manager and assisted with data analysis. M.D. and Y.P. 13. Sibiude J, Mandelbrot L, Blanche S, et al. Association between prenatal exposure
to antiretroviral therapy and birth defects: An analysis of the French perinatal
serve as the national co-ordinators of this surveillance cohort study (ANRS CO1/CO11). PLoS Med. 2014;11(4):e1001635. https://doi.
org/10.1371/journal.pmed.1001635
system and provided technical, administrative and policy 14. Knapp KM, Brogly SB, Muenz DG, et al. Prevalence of congenital anomalies
support for this surveillance system. in utero exposure to antiretrovirals. Pediatr Infect Dis J. 2012;31(2):164–170.
https://doi.org/10.1097/INF.0b013e318235c7aa
15. Conroy AL, McDonald CR, Gamble JL, et al. Altered angiogenesis as a common
Funding mechanism underlying preterm birth, small for gestational age, and stillbirth
in women living with HIV. Am J Obs Gyn. 2017;217(6):684 e1–14. https://doi.
The surveillance system is supported by financial org/10.1016/j.ajog.2017.10.003
contributions from PEPFAR (United States President’s 16. Zash R, Jacobson DL, Diseko M, et al. Comparative safety of antiretroviral
treatment regimens in pregnancy. JAMA Paed. 2017;171(10):e172222. https://
Emergency Plan for AIDS Relief), the World Health doi.org/10.1001/jamapediatrics.2017.2222
Organization and the South African National Department of 17. Zash R, Souda S, Chen JY, et al. Reassuring birth outcomes with tenofovir/
emtricitabine/efavirenz used for prevention of mother-to-child transmission of
Health. This publication was made possible through the HIV in Botswana. J Acquir Immune Defic Syndr. 2016;71(4):428–436. https://doi.
org/10.1097/QAI.0000000000000847
support provided by the US Agency for International 18. Uthman OA, Nachega JB, Anderson J, et al. Timing of initiation of antiretroviral
Development to MatCH (Maternal, Adolescent and Child therapy and adverse pregnancy outcomes: A systematic review and meta-analysis.
Lancet. 2017;4(1):e21–e30. https://doi.org/10.1016/S2352-3018(16)30195-3
Health) under the terms of Contract No. AID-674-A-12-00019. 19. Papp E, Mohammadi H, Loutfy MR, et al. HIV protease inhibitor use during
The opinions expressed herein are those of the authors and pregnancy is associated with decreased progesterone levels, suggesting a
potential mechanism contributing to fetal growth restriction. J Infect Dis.
do not necessarily reflect the views of the US Agency for 2015;211(1):10–18. https://doi.org/10.1093/infdis/jiu393
International Development. 20. Ford N, Mofenson L, Shubber Z, et al. Safety of efavirenz in the first trimester of
pregnancy: An updated systematic review and meta-analysis. AIDS. 2014(Suppl
2):S123–S131. https://doi.org/10.1097/QAD.0000000000000231
Data availability statement 21. Siberry GK, Williams PL, Mendez H, et al. Safety of tenofovir use during pregnancy:
Early growth outcomes in HIV-exposed uninfected infants. AIDS. 2012;26(9):
1151–1159. https://doi.org/10.1097/QAD.0b013e328352d135
Data sharing is not applicable to this article as no new data 22. Van Dyke RB, Chadwick EG, Hazra R, et al. The PHACS SMARTT Study: Assessment
were created or analysed in this study. of the safety of in utero exposure to antiretroviral drugs. Front Immunol. 2016.
http://doi.org/10.3389/fimmu.2016.00199
23. Antiretroviral Pregnancy Registry Steering Committee, Antiretroviral pregnancy
Disclaimer registry international interim report for 1 January 1989 through 31 January
2018 [homepage on the Internet]. [cited 2018 Oct 23]. Wilmington, NC: Registry
Coordinating Centre. Available from: www.apregistry.com
The views expressed in the article are those of the authors 24. US Department of Health and Human Services, AIDSinfo: Recommendations
and not an official position of the institution or funder. for the use of antiretroviral drugs in pregnant women with HIV infection and
interventions to reduce perinatal HIV transmission in the United States [cited 2019
Apr 27]. Available from: https://aidsinfo.nih.gov/guidelines/html/3/perinatal/204/
nevirapine--viramune--nvp-
References 25. Zash RM, Williams P, Holmes LB. What is the risk of major congenital abnormalities
among women on antiretroviral therapy? AIDS. 2018;32(3):403–404. https://doi.
1. Moodley J, Fawcus S, Pattinson R. Improvements in maternal mortality in org/10.1097/QAD.0000000000001711
South Africa. SAMJ. 2018;3(suppl1):S4–S8. 26. Prestes-Carneiro LE. Antiretroviral therapy, pregnancy, and birth defects:
2. Govender T, Coovadia H. Eliminating mother to child transmission of HIV-1 and A discussion on the updated data. HIV AIDS. 2013;5:181–189. https://doi.
keeping mothers alive. J Infect. 2014;68(1):S57–S62. https://doi.org/10.1016/j. org/10.2147/HIV.S15542
jinf.2013.09.015 27. Siberry GK, Jacobson DL, Kalkwarf HJ, et al. Lower newborn bone mineral content
3. WHO. Consolidated guidelines on the use of antiretroviral drugs for treating associated with maternal use of tenofovir disoproxil fumarate during pregnancy.
and preventing HIV infection: Recommendations for a public health approach Clin Infect Dis. 2015;61(6):996–1003. https://doi.org/10.1093/cid/civ437
[homepage on the Internet]. 2013 [cited 2018 Oct 3]. Available from: https://
apps.who.int/iris/bitstream/handle/10665/85321/9789241505727_eng.pdf 28. The 2015 National Antenatal Sentinel HIV and Herpes Simplex type-2 prevalence
Survey [homepage on the Internet]. South Africa: National Department of
4. National Department of Health, South Africa. National Consolidated guidelines Health [cited 2018 Oct 23]. Available from: http://www.health.gov.za/index.
for the prevention of mother-to-child transmission of HIV (PMTCT) and the php/shortcodes/2015-03-29-10-42-47/2015-04-30-08-18-10/2015-04-30-08-21-
management of HIV in children, adolescents, and adults [homepage on the 56?download=2584:2015-national-antenatal-hiv-prevalence-survey-final-23oct17
Internet]. 2013 [cited 2019 Apr 27]. Available from: https://sahivsoc.org/Files/
ART%20Guidelines%2015052015.pdf 29. Massyn N, Padarath A, Peer N, et al., editors. District Health Barometer 2016/17
[homepage on the Internet]. Durban: Health Systems Trust; 2017 [cited 2018
5. Powis KM, Kitch D, Ogwu A, et al. Increased risk of preterm delivery among HIV- Oct 23]. Chapter 5, p. 77. Available from: http://www.hst.org.za/publications/
infected women randomized to protease versus nucleoside reverse transcriptase District%20Health%20Barometers/5%20(Section%20A)%20PMTCT.pdf
inhibitor-based HAART during pregnancy. J Infect Dis. 2011;204(4):506–514.
https://doi.org/10.1093/infdis/jir307 30. World Health Organization/Centers for Disease Control and Prevention/
International Clearinghouse for Birth Defects Surveillance and Research (WHO/
6. Malaba TR, Phillips T, Le Roux S, et al. Antiretroviral therapy use during CDC/ICBDSR). Birth defects surveillance: A manual for programme managers
pregnancy and adverse birth outcomes in South African women. Int J Epidemiol. [homepage on the Internet]. Geneva: World Health Organization; 2014 [cited
2017;46(5):1–12. https://doi.org/10.1093/ije/dyx136 2018 Oct 23]. Available from: https://www.who.int/nutrition/publications/
7. Ramokolo V, Goga A, Lombard C, et al. In utero ART exposure and birth and early birthdefects_manual/en/.
growth outcomes among HIV-exposed uninfected infants attending immunization 31. Holmes LB, Westgate MN. Inclusion and exclusion criteria for malformations in
services: Results from national PMTCT surveillance. Open Forum Infect Dis. newborn infants exposed to potential teratogens. Birth Defects Res A Clin Mol
2017;4(4):ofx187. https://doi.org/10.1093/ofid/ofx187 Teratol. 2011;91(9):807–812. https://doi.org/10.1002/bdra.20842
http://www.sajhivmed.org.za 365 Open Access